Trial Profile
Safety, tolerability, pharmacokinetics of single ascending dose and multiple ascending doses of CC-11050, food effect of CC-11050, and drug interaction of CC-11050 with isoniazid plus rifampin or isoniazid plus rifabutin: A phase I study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Mar 2018
Price :
$35
*
At a glance
- Drugs Dovramilast (Primary) ; Isoniazid; Rifabutin; Rifampicin
- Indications Cutaneous lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics
- 28 Mar 2018 New trial record
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics